[Form 3] GlycoMimetics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Nuveen Quality Municipal Income Fund (NAD) submitted a LIVE Form NPORT-P monthly portfolio report to the SEC; however, the excerpt provided is largely a blank template with placeholder rows and no populated financial data.

The filing confirms only that it is not the Fund’s final submission (Item A.4 shows “No”) and that non-cash collateral may have been accepted in securities-lending transactions (Item B.4.b offers a Yes/No choice but no selection is shown). Key quantitative sections—assets, liabilities, risk metrics, monthly returns, and share-flow information—contain no figures. As such, investors receive no insight into portfolio composition, leverage, risk, or recent performance from this excerpt.

Insights

Registered Investment Company Analyst

TL;DR: Filing template reveals almost nothing—no numbers, no positions, minimal disclosures; therefore limited investment relevance.

This NPORT-P extract merely establishes a procedural fact: NAD filed a monthly portfolio report in LIVE mode. All material financial fields (assets, liabilities, DV01, returns, cash flows) are blank, so the document provides no actionable data on credit exposure, duration, or liquidity. Given the absence of populated metrics, the filing neither enhances transparency nor signals risk. From a compliance view, the Fund meets its obligation to file, but the utility to investors is negligible.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Violin Jonathan

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/13/2025

3. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [ CBIO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	69,515(1)(2)(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)(2)(4)	12/11/2034	Ordinary Shares	226,786	$6.16	D

Explanation of Responses:

1. Effective as of June 13, 2025 (the "Effective Time"), (i) a wholly-owned subsidiary of GlycoMimetics, Inc. ("GlycoMimetics") merged with and into Crescent Biopharma, Inc. ("Pre-Merger Crescent") with Pre-Merger Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the "First Merger"), (ii) immediately thereafter, Pre-Merger Crescent merged with and into a second wholly-owned subsidiary of GlycoMimetics ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Crescent Biopharma Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, GlycoMimetics changed its name to "Crescent Biopharma, Inc." (hereinafter, the "Issuer").

2. This Form gives effect to the Issuer's completion of a conversion from a corporation organized under the laws of the State of Delaware (the "Delaware Corporation") to an exempted company incorporated under the laws of the Cayman Islands (the "Cayman Company"), effective as of June 16, 2025. In connection therewith, (a) each outstanding share of common stock of the Delaware Corporation was automatically converted into one ordinary share of the Cayman Company; and (b) each outstanding option or right to acquire shares of common stock of the Delaware Corporation continued in existence in the form of and automatically became an option or right to acquire an equal number of ordinary shares of the Cayman Company under the same terms and conditions.

3. Represents ordinary shares of the Issuer received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Crescent's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Crescent's restricted common stock held at the Effective Time was exchanged for 0.1445 restricted ordinary shares of the Issuer. Of these ordinary shares, 20,164 are restricted and will vest as to 25% on September 28, 2025 and in equal monthly installments thereafter through September 28, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

4. Represents options to purchase the Issuer's ordinary shares received by the Reporting Person in the Merger in exchange for options of Pre-Merger Crescent held by the Reporting Person prior to the Merger. These options are fully vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Barbara Bispham, as attorney-in-fact for Jonathan Violin	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is Nuveen Quality Municipal Income Fund's (NAD) latest SEC filing type?

Form NPORT-P, a monthly portfolio investments report.

Is the Form NPORT-P filing for NAD marked as LIVE or TEST?

The excerpt indicates the submission is in LIVE mode.

Does the filing state this is NAD’s final NPORT-P report?

Item A.4 lists a Yes/No option; "No" is indicated, so it is not final.

Are any asset or liability figures disclosed in this excerpt?

No. All asset, liability, and risk metric fields are blank in the provided content.

Does the filing show whether non-cash collateral was provided in securities lending?

Item B.4.b presents a Yes/No checkbox, but no selection is shown in the excerpt.